Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Impact of Mutational Landscape and Biomarkers on Response of Luspatercept (ACE-536) Treatment of Anemia in Non-Transfusion Dependent IPSS-R Lower Risk MDS Japanese Subjects (ACE-536-MDS-003- a Ph2 single-arm study)

Bijay Shankar Jaiswal, Manuel Ugidos, Hiroshi Kosugi, Kosei Matsue, Hiromi Murakami, Jin Hayakawa, Daniel Lopes de Menezes, Anita K. Gandhi, Rajasekhar N.V.S. Suragani

Blood (2024) 144 (Supplement 1): 6725.

https://doi.org/10.1182/blood-2024-201883

Published: 2024

Journal Articles

Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

Jan Philipp Bewersdorf, Vanessa Hasle, Rory M. Shallis, Ethan G. Thompson, Daniel Lopes De Menezes, Shelonitda Rose, Isaac W. Boss, Lourdes Mendez, Nikolai A. Podoltsev, Maximilian Stahl, Tariq Kewan, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 4585.

https://doi.org/10.1182/blood-2024-194929

Published: 2024

Journal Articles

Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial

Danny Jeyaraju, Sheida Hayati, Jia Wang, Claire N Harrison, Jean-Jacques Kiladjian, Christopher Hernandez, Patrick Brown, Daniel Lopes De Menezes, Anita K. Gandhi, Rajasekhar N.V.S. Suragani

Blood (2023) 142 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2023-180419

Published: 2023

Journal Articles

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Daniel Lopes De Menezes, Manuel Ugidos Guerrero, Arnaud Amzallag, Wendy L. See, Alberto Risueno, Charalampos Kyriakopoulos, Rajasekhar N.V.S. Suragani, Barry S. Skikne, C.L. Beach, Thomas Prebet, Maria Teresa Voso, Andre C. Schuh, Gail J. Roboz, Hartmut Döhner, Andrew H. Wei, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2023-187651

Published: 2023

Journal Articles

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

Danny V Jeyaraju, Sheida Hayati, Ann Polonskaia, Maryam Alapa, Manuel Ugidos, Andrew Browne, Alberto Risueño, Patrick Hagner, Vikas Gupta, Moshe Talpaz, Christopher Hernandez, Vincent Chia, Patricia Martin-Regueira, Daniel Lopes de Menezes, Ross La Motte-Mohs, Rajasekhar NVS Suragani, Anita K. Gandhi

Blood (2022) 140 (Supplement 1): 3865–3867.

https://doi.org/10.1182/blood-2022-166407

Published: 2022

Journal Articles

Impact of Allelic State on Overall Survival in TP53- mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)

Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan G. Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac W. Boss, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan

Blood (2022) 140 (Supplement 1): 8910–8911.

https://doi.org/10.1182/blood-2022-158592

Published: 2022

Journal Articles

Molecular, Epigenetic, and Immune Landscape of TP53- mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)

Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan G. Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac W. Boss, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan

Blood (2022) 140 (Supplement 1): 6247–6249.

https://doi.org/10.1182/blood-2022-156460

Published: 2022

Journal Articles

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R. Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther T. Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes

Blood (2022) 140 (15): 1674–1685.

https://doi.org/10.1182/blood.2022016293

Published: 2022

Includes: Supplemental data

Journal Articles

Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)

Courtney D. DiNardo, Gautam Borthakur, Brian Ball, Harry P. Erba, Raya Mawad, Marina Kremyanskaya, James S. Blachly, Hetty E. Carraway, Ahrim Youn, Jessica Garzon, Daniel Lopes de Menezes, Patricia Martin-Regueira, C.L. Beach, Justin Watts

Blood (2021) 138 (Supplement 1): 4430.

https://doi.org/10.1182/blood-2021-146791

Published: 2021

Journal Articles

OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

Farhad Ravandi, Hetty E. Carraway, Lilia Taningco, Kimberley Dilley, Eric Laille, Jing Gong, Daniel Lopes de Menezes, Andrew H. Wei

Blood (2021) 138 (Supplement 1): 2314.

https://doi.org/10.1182/blood-2021-147293

Published: 2021

Journal Articles

Low Exposure Extended Dosing Mimicking Clinical Exposures of the Oral Formulation of Azacitidine Results in a Sustained Hypomethylation and Targets Leukemic Stem Cells

Danny V Jeyaraju, Maryam Alapa, Ann Polonskaia, Alberto Risueño, Aarif Ahsan, Chao Wang, Prakash Subramanyam, Jammula Sriganesh, Amit Anand, Gaurav Jain, Madhusudhan Reddy, Kaushik Ghosh, Charalampos Kyriakopoulos, Nathalie Lailler, Christopher Hartl, Daniel Lopes de Menezes, Patrick Hagner, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2021-153523

Published: 2021

Journal Articles

Immune and Epigenetic Landscape of TP53- mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Amer M. Zeidan, Jan Philipp Philipp Bewersdorf, Vanessa Hasle, Ethan G. Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac Boss, Brian Fox

Blood (2021) 138 (Supplement 1): 3371.

https://doi.org/10.1182/blood-2021-146329

Published: 2021

Journal Articles

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes

Blood (2021) 138 (Supplement 1): 804.

https://doi.org/10.1182/blood-2021-147465

Published: 2021

Journal Articles

CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

Diana R. Dunshee, Yumin Dai, Jessica C. Jang, Alberto Risueño, Danny V Jeyaraju, Patrick Hagner, PhD, Wendy L. See, Kyle MacBeth, Xiaomin Wang, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Anjan Thakurta, Daniel Lopes de Menezes, PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-137606

Published: 2020

Journal Articles

Rap-536 Induces Reticulocyte Maturation in Wild-Type Mice, Increases Survival of Beta-Thalassemic Reticulocytes, and Increases Red Blood Cells in a Mouse Model of Alpha-Thalassemia

Melih Acar, Madhulika Jupelli, Roberto A. Abbiati, Harish N. Ramanathan, Cristina C. Santini, Alexander Ratushny, Diana R. Dunshee, Daniel Lopes de Menezes, PhD, Kyle MacBeth, Rajasekhar N.V.S. Suragani, Remco Loos, Martin Schwickart

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-137373

Published: 2020

Journal Articles

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gail J. Roboz, MD, Farhad Ravandi, MBBS, Andrew H Wei, MBBS, PhD, Hervé Dombret, MD, Hartmut Döhner, Felicitas Thol, Maria Teresa Voso, MD, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Alberto Risueño, Daniel Lopes de Menezes, PhD, Gert Ossenkoppele, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140837

Published: 2020

NARROW

Impact of Mutational Landscape and Biomarkers on Response of Luspatercept (ACE-536) Treatment of Anemia in Non-Transfusion Dependent IPSS-R Lower Risk MDS Japanese Subjects (ACE-536-MDS-003- a Ph2 single-arm study)

Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

Impact of Allelic State on Overall Survival in TP53- mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)

Molecular, Epigenetic, and Immune Landscape of TP53- mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)

OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

Low Exposure Extended Dosing Mimicking Clinical Exposures of the Oral Formulation of Azacitidine Results in a Sustained Hypomethylation and Targets Leukemic Stem Cells

Immune and Epigenetic Landscape of TP53- mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

Rap-536 Induces Reticulocyte Maturation in Wild-Type Mice, Increases Survival of Beta-Thalassemic Reticulocytes, and Increases Red Blood Cells in a Mouse Model of Alpha-Thalassemia

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only